A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study of Intravenous Staphylococcal Protein A in Patients with Active Rheumatoid Arthritis On Methotrexate

Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study of Intravenous Staphylococcal Protein A in Patients with Active Rheumatoid Arthritis On Methotrexate

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Apr 2015

At a glance

  • Drugs Staphylococcal-protein-A (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Protalex
  • Most Recent Events

    • 16 Apr 2015 Following an exploratory biomarker analysis of data from the PRTX100-104 study, Protalex intends to re-examine biomarkers from this trial and perform combined analysis of the 103 Study and 104 Study biomarkers, according to a media release.
    • 15 Aug 2013 Results will be published in the Journal of Clinical Pharmacology according to a Protalex media release.
    • 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top